The GIP Arronax and Curium PET France have partnered to co-operate the new 18 MeV Cyclotron. This technology will enable the production of radiopharmaceutical drugs such as Fluorine-18:
“When we decided to acquire a new cyclotron to produce more radionuclides and further our R&D efforts, we aimed to share our beam time with an industrial partner to contribute to better supply of radiopharmaceuticals based on Fluorine-18 in the region,” explains Tony Prézeau, Director of Valorization at GIP ARRONAX. “We are particularly proud to host Curium PET France, a leader in this field, at our site. The signing of this partnership, alongside the arrival of our second cyclotron, undoubtedly marks a new milestone in the history of GIP ARRONAX, which is dedicated to conducting both economic and research activities.”
The Public Interest Group (GIP) Arronax was created in 2008 to support the operation of the Arronax cyclotron (Accelerator for Research in Radiochemistry and Oncology in Nantes Atlantique), unique in the world for its characteristics and mission to support medical research, especially nuclear medicine.
GIP Arronax is one of the 11 partners of SIRIC ILIAD and is particularly involved in the work of WP2, WP7 et WP8
More information can be found in the press release.
